CHAPTER-26

AUTHORS' INFORMATION

Dr. Manmohan has secured his PhD in Life Science from Bangalore University. He is currently working as Faculty of Department of Life Science, Bangalore University. His teaching areas include Microbiology, Pathology, Parasitology, Immunology, Molecular biology, Evolutionary Biology, Applied Biology, Environmental Biology, etc. He has also guided post graduate students for their research project. He has decent track of published research articles and presented his works in national and international conferences and symposia.

Dr. Neha Keral is a Research Analyst in Vyuhgenics India Pvt. Ltd., a US based Biotech and Healthcare Company located in Bengaluru, Karnataka, India. She obtained Ph.D. in Life Science, from Bangalore University. She has assisted in practical classes and guided post graduate students in their dissertation projects during her research tenure. Dr. Keral is a receiver of National Bal Jyoti Scholarship given by NIIT. She had participated in Dainik Jagran Rally of Control Pollution & Save Environment organized by Ministry of Information and Technology. She has published research articles in peer reviewed international journals and presented number of works in national, international conferences and symposia.

Open Access Full Text Article
https://doi.org/10.26524/royal.37.26

CHAPTER-26

THE GLOBAL RACE FOR MOST AWAITED VACCINE AGAINST COVID-19

Neha Keral[1], Manmohan M.S[2*]

[1]VYUHGENICS Ind.Pvt.Ltd

Bangalore, India

[2]Department of Life Sciences, Bangalore University, Bangalore, Karnataka, India

Corresponding author:

Dr. Manmohan M.S.

E-mail:
manmohan.mana@gmail.com

Keywords

COVID-19

VACCINE

GLOBAL

ABSTRACT

The report is based on the currently developed vaccination for COVID-19. Due to COVID-19, the whole world is facing problems. The situation is going to be pathetic day by day. It attacks the aged people heavily and they are going to die. There was no availability of medicine. In medical science also there was no such kind of description of medicine. Only by increasing the immunity power, doctors are trying to save the life of patients. The descriptions of the development of medicine are discussed throughout the report.

1. Introduction

A COVID-19 vaccine is biotechnology aimed for providing immunity in opposition to COVID-19 in 2019. At first, vaccines were developed by 218 vaccine candidates in July 2020. But no one candidate till now has accomplished clinical trials to confirm its efficacy and safety. Vaccine candidates were declared around 24 that they were going for trials in clinic, two candidates are starting Phase three, and also seven candidates are in Phase one to two. Formers are trying to improve a vaccine at odds with coronavirus SARS, with it

also MERS asserted significant knowledge of learning regarding the function and structure of coronaviruses which developed rapidly in this current year 2020, based on different platforms of technology for coronavirus vaccine but the former vaccine candidates are being failed in the first stage of trials in clinic, without any advancement of approveness. The Coalition for Epidemic Preparedness Innovations (CEPI) that is forming 2 US billion dollars universal funds to accelerate dedication, and also improvement of vaccine candidates that pointed out in April. Vaccines are maybe obtainable under emergency for applying in fewer amounts by early 2021. The WHO established a telethon that accepted around 8.1 US billion dollars in undertaking from forty countries for providing the help in the rapid improvement of vaccines to confine COVID-19 infections on 4 May in this year. The WHO also declared at that time expansion of international "Solidarity trail" for contemporaneous estimation of more vaccine candidates coming at Phase two-three trials in clinic.

2. The pandemic of COVID-19:

From the last six months, the speed of COVID-19 is increasing in such a manner that 6 million people have infected. And 380,000 people have killed by the effect of this COVID-19. It became the biggest challenge for all over the world. A vaccine is urgently required to stop this condition. All counties over the world are trying their level best to invent the vaccine. Many companies are contesting to make a COVID-19 vaccine. On 12th May 2020, the USA government announced that this vaccine of COVID-19 could be available by the end of this year. The World Health Organization expects that in between 1.5-2 years, the COVID-19 vaccine will be available. A quick recovery from biology revives us about the immunity induced by the common viruses and immunization. Microorganisms cause many human diseases. When a body contacts these microbes includes the viruses, bacteria, fungi, or parasites, its immune system plays a vital role. It protects our bodies from these pathogens. As our immune system will run smoothly, you won't notice any diseases [1]. The immune system of our body responds against the pathogen. The immune system provides antimicrobial peptides to stimulate the cells of the body. The white blood cells of our blood also detect whether a substance does belong to our body

or not. The immune system provides an antibody to protect our bodies. To make this antibody, it takes 2-8 weeks. It is very naturalistic to fall in sick or recovering from an infection, but the only thing is to acquire immunity to it. If we expose to the same pathogen frequently, our body spots the pathogens and give a quick response to it. The necessity of a vaccine is to develop the immunity power. It helps to terminate the severity of the disease. It can accelerate the immune system to respond to the pathogens by creating antibodies. Scientists have already succeeded by inventing vaccine to prevent the disease such as smallpox, chickenpox, polio, measles, and recently Ebola disease. To create a vaccine is not as easy as we think. In realism, the task of creating a vaccine is a very complicated and sky-high task with unpredictable results. If one could establish a vaccine, to initiate with that, the person has must be tested in experimental animals to assure that it is not poison in any way. Usually, the developer of the vaccine goes along with some specific steps. The number of factors is studied here. The main factor that is involved:

- **Safety and Security:**

First of all, it is essential to more that the vaccine is safe to use or not. Vaccines are must be tested if there are any other risks involved with it.

- **Cost:**

Before initiating, the cost of raw material should have considered for a vaccine. We have to consider how many skilled professionals are required to act on it.

- **Efficiency:**

Once a vaccine has developed, it needs to determine whether it works well or not. By organizing the clinical trials, efficiency can ensure.

- **The timespan of the immunity:**

The most important determinant is how much longer the vaccine persists. The developer needs to so strong that their vaccine is healthy and vigorous enough to keep on providing immune power.

3. Globally Accelerated Improvement:

After detecting the pneumonia of novel coronavirus in December 2019, genetic series of coronavirus was revealed on January 11 in next year, set off a serious response

internationally to ready for the prevalence, with it also precipitate the improvement of the preventative vaccine [2]. Instantaneously, the increasing infection rate of coronavirus globally at the time of early 2020 sharpened international alliances, also government exertions for arranging the resources urgently to create several vaccines during a very short time, with only four vaccine aspirants entering human rating on March. A vaccine for a contagious disease has not been made in less than more years, and also no vaccine outflows to stop the disease of coronavirus. On April CEPI allows that six of 115 vaccine aspirants against this novel coronavirus would be selected by international coalitions for improvement depending on Phase two-three trials, along with also three must be lined through governing and also undertaking the quality for ultimate approving at a total expenditure of minimum 2 US billion dollars [3]. Ten candidates simultaneously will require for improvement initially before an elect few are selected for the ultimate way for licensing. The vaccine exertion is being set up with the speed of evaluation of harsh clinical for efficacy and safety, planning and financing for generating billions of doses, also consequent global expansion and unprejudiced portal among advanced and untrained countries [4]. CEPI, WHO are pledging money, and also organizational sources for the expectation of those different vaccines, will be required for destroying this continuing coronavirus infection. Custom production of the vaccines will need with packaging, transportation, also storage in a total of 200 countries with transited citizens. The WHO organization allots the total price of 8 billion US dollars for developing three or more than three vaccines that have uses the various technologies and try to prevent the infections of COVID-19 worldwide.

4. International Organizations

International alliances have been formed by organizations for the expedition of development and preparation of the vaccine. Finally, the vaccine needs to be distributed. The WHO is included among the organizations that are providing collaboration, accelerating research, facilitating international communication on a scale that is unknown in history [5]. For helping in vaccine development globally, the WHO has implemented and procedure that is providing acceleration to developed COVID -19 tools. The WHO

declared in July 2020 that, 165 countries represent about 60% of the world population, will be provided the equal distribution of the licensed vaccine. Also WHO makes it guaranteed that by the end of the year 2021, around 20 percent of the population of each country belongs to those 165 countries, will be vaccinated. The CEPI stands for Coalition for Epidemic Preparedness Innovations that are working with international health authorities also with the developers of vaccine for creating another 8 billion of US dollars with the help of partnership in globally. In the month of May the United Kingdom, Belgium, Canada, Norway, and some other countries already pay around 195 billion US dollars to CEPI. For research of COVID-19 Vaccine, one charitable organization also donates around 250 billion US dollars to the CEPI. The GLoPID is also helping WHO for research purposes in a number of stages.

5. National Governments

For international and national research of vaccines, the national governments are also dedicating the resources. Also, the governments are investing money in the manufacturing of the vaccine in 2020 [6]. The governments already invested in 96 research projects of COVID-19 in Canadian companies. Another investment is related to the clinical trials in Canada that are cost around CA$1.1 billion. The Canadian government is also provided $850 million to the WHO for research and vaccine development purposes. The China government is providing loans in low-interest rates with the help of the Central bank for the development of the vaccine. In the month of June in 2020, from the twelve vaccines, the six vaccines are in their early stage of human testing produced with the help of the Chinese Organization. So the governments are supporting the Chinese companies of vaccines for early research and development of the vaccine.

6. The Vaccines of COVID-19:

In an excellent effort to address this danger, some of the institutions have struggled. For clinical trials, ten separate vaccine applicants are now present. In Cambridge, Moderna is a biotech company where candidates of COVID-19 based on the mRNA platform [7]. The mRNAs are the mediators to take genetic information collected in the DNA for making the protein in the cell that reads the encoded instructions and

forms proteins. With the help of these proteins, various functions of these cells in our bodies are performing. The applicant of vaccine mRNA-1273 stocks the guide to creating the SARS-CoV-2 S protein, which is decoded by this method for exciting the immune system. Here 45 healthy volunteers were managed before this animal trial accomplish. On 12th May, Moderna declared that to accelerate its development, it had to accept the fast track designation of the US FDA. In a single week, the Moderna declared that mRNA-1273 was harmless, safe, well-performed, and provoked immunizer responses similar to those sufferers who had already recovered from COVID-19. On 18th may, in this announcement, this Company declared that its applicants protected from the virus. Oxford University vaccines depend on some common harmless viruses. For forming the S protein, it is transforming to carry the genetic instructions. Also, this formation is known for ChAdOx1nCoV-19. In the last week of April, this vaccine is already inscribed for human trials to recruit more than 1100 healthy adults. On 13th May, the outcomes of treating monkeys with this vaccine have posted as an article, applicant of vaccines has protected some specific monkeys from pneumonia. In the time when the monkeys experimented with a nasal swab in the presence of SARS-CoV-2, there is no notable variation between immunized and unimmunized monkeys. In this way, the effects of this vaccine are in the same way in humans. Oxford Institute is initiating to planning the trials of stage 2 and stage 3 [8]. Not only, The Moderna has been innovated a successful vaccine for the disease, but The Oxford Institute has also innovated its vaccine for some other bugs. Instead of this, in clinical trials, there are also eight more applicants are present. Among the eight applicants, five from China and some are from the USA. Another vaccine is Mynvax. Bengaluru based health care provider announced work on the COVID-19 vaccine. It is the same research that has already completed in the Indian Institute of Science. The Ahmedabad-based pharmaceutical startup announced the testing process of vaccine applicant marked ZyCOV-D in last week. In the same research for the extensive process was completed in collaboration with the laboratories in the USA. Other vaccine makers in India advertised the progress of vaccines by a partnership with the Griffith University of Australia. Here pre-clinical experiments are still running on. Indian Medical

Association has asserted a vaccine for coronavirus, after 2020, due to the improvement, and retailing can lead to the proper stage. Further, technological advances should be look into along the side to combat COVID-19 [9].

Conclusion

Throughout the discussion, we come to this conclusion that a reliable, efficient, and low-priced vaccine is required. It is most important to stop this pandemic situation. It is not possible to avoid this situation at once. It is expected that a vaccine could work for some, but not for all. Such a vaccine is becoming a requirement for all. It may not be equally affordable to all the countries, so the world needs to learn to manage it. If one country also could not get the vaccine, the SARS-Cov-2 virus will continue to persist. So we should join our hands together and should aware to free from this daredevil.

REFERENCES

1. Escobar & Barillas-Mury, C. (2020). BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). *Proceedings of the National Academy of Sciences*, *117*(30), 17720-17726.
2. Kim, S. J. (2020). Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19).
3. Halton, J. (2020). Developing Covid-19 vaccines at pandemic speed. *New England Journal of Medicine*, *382*(21), 1969-1973.
4. Otazu, G. H. (2020). Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. *MedRxiv*.
5. Albaiu, D. (2020). Research and development on therapeutic agents and vaccines for COVID-19 and related human coronavirus diseases.
6. Ketloy, C., &Palaga, T. (2020). Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. *Asian Pac J Allergy Immunol*, *38*(1), 1-9.
7. Gates, B. (2020). Responding to Covid-19—a once-in-a-century pandemic?.*New England Journal of Medicine*, *382*(18), 1677-1679.

8. Mayhew, S. (2020). The COVID-19 vaccine development landscape. *Nat Rev Drug Discov*, *19*(5), 305-306.
9. R.R. Nadikattu, S. M. Mohammad, and P. Whig, " Novel Economical Social Distancing Smart Device for COVID-19 (July 1, 2020)". International Journal of Electrical Engineering and Technology (IJEET), 11 (4),204-217, 2020.